Quick Answer
VACCINEX, INC. reported R&D Expense of $12.54 million for fiscal year 2024.
VACCINEX, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $12.54M | -24.3% |
| 2023 | $16.57M | +18.6% |
| 2022 | $13.98M | -18.5% |
| 2021 | $17.16M | -20.4% |
| 2020 | $21.55M | -16.1% |
| 2019 | $25.67M | +14.8% |
| 2018 | $22.35M | +35.1% |
| 2017 | $16.55M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $3.17M | -27.3% | -18.1% |
| June 30, 2024 | $3.86M | -23.5% | +14.2% |
| March 31, 2024 | $3.38M | -11.3% | -22.3% |
| September 30, 2023 | $4.36M | +27.0% | -13.8% |
| June 30, 2023 | $5.05M | +31.4% | +32.5% |
| March 31, 2023 | $3.81M | +28.5% | +11.2% |
| September 30, 2022 | $3.43M | -5.5% | -10.8% |
| June 30, 2022 | $3.84M | -5.4% | +29.6% |
- VACCINEX, INC. showed a decrease of -24.3% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2024 period, VACCINEX, INC.’s r&d expense has declined by 24.2% (from $16.55 million to $12.54 million).
- The most recent figure is from VACCINEX, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: